The role of stroma in immune recognition and destruction of well-established solid tumors
- PMID: 16459066
- DOI: 10.1016/j.coi.2006.01.004
The role of stroma in immune recognition and destruction of well-established solid tumors
Abstract
Well-established solid tumors (at least 14 days old and >1cm in average diameter) are extremely difficult to eradicate immunologically in mice. Most cancer patients that seek medical attention bear primary or metastatic tumors that have grown for longer and that are larger than the tumors we call established. Therefore, focusing research on the problems of rejecting well-established mouse tumors might help in the development of novel concepts and protocols for destroying tumors in patients. A particular problem with established cancers is that even when treatments induce temporary regression, cancer often recurs. Recent studies suggest that manipulation of the stromal microenvironment of these tumors can induce immune recognition and regression. Furthermore, targeting cancer cells as well as tumor stroma for immune destruction might be needed to prevent recurrence.
Similar articles
-
Targeting the stroma by T cells to limit tumor growth.Cancer Res. 2008 Dec 1;68(23):9570-3. doi: 10.1158/0008-5472.CAN-08-2414. Cancer Res. 2008. PMID: 19047130 Review.
-
Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.Immunotherapy. 2011 Oct;3(10):1253-64. doi: 10.2217/imt.11.124. Immunotherapy. 2011. PMID: 21995575 Review.
-
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.Handb Exp Pharmacol. 2008;(181):291-328. doi: 10.1007/978-3-540-73259-4_13. Handb Exp Pharmacol. 2008. PMID: 18071951 Review.
-
From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.Adv Anat Pathol. 2007 May;14(3):149-77. doi: 10.1097/PAP.0b013e3180504abf. Adv Anat Pathol. 2007. PMID: 17452813 Review.
-
Immune cells as mediators of solid tumor metastasis.Cancer Metastasis Rev. 2008 Mar;27(1):11-8. doi: 10.1007/s10555-007-9100-0. Cancer Metastasis Rev. 2008. PMID: 18066650 Review.
Cited by
-
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway.Am J Pathol. 2010 May;176(5):2082-7. doi: 10.2353/ajpath.2010.091173. Epub 2010 Mar 12. Am J Pathol. 2010. PMID: 20228228 Free PMC article. Review.
-
The solid tumor microenvironment and related targeting strategies: a concise review.Front Immunol. 2025 Mar 26;16:1563858. doi: 10.3389/fimmu.2025.1563858. eCollection 2025. Front Immunol. 2025. PMID: 40207238 Free PMC article. Review.
-
Combination of viral oncolysis and tumor-specific immunity to control established tumors.Clin Cancer Res. 2009 Jul 15;15(14):4581-8. doi: 10.1158/1078-0432.CCR-08-2685. Epub 2009 Jul 7. Clin Cancer Res. 2009. PMID: 19584165 Free PMC article.
-
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.J Immunother Cancer. 2023 Aug;11(8):e007199. doi: 10.1136/jitc-2023-007199. J Immunother Cancer. 2023. PMID: 37586774 Free PMC article.
-
Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis.Gastroenterol Rep (Oxf). 2019 Dec 5;8(1):56-65. doi: 10.1093/gastro/goz060. eCollection 2020 Feb. Gastroenterol Rep (Oxf). 2019. PMID: 32104586 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous